The fungal product terreic acid is a covalent inhibitor of the bacterial cell wall biosynthetic enzyme UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA) .
Terreic acid is a metabolite with antibiotic properties produced by the fungus Aspergillus terreus. We found that terreic acid is a covalent inhibitor of the bacterial cell wall biosynthetic enzyme MurA from Enterobacter cloacae and Escherichia coli in vitro. The crystal structure of the MurA dead-end complex with terreic acid revealed that the quinine ring is covalently attached to the thiol group of Cys115, the molecular target of the antibiotic fosfomycin. Kinetic characterization established that the inactivation requires the presence of substrate UNAG (UDP-N-acetylglucosamine), proceeding with an inactivation rate constant k(inact) of 130 M(-1) s(-1). Although the mechanisms of inactivation are similar, fosfomycin is approximately 50 times more potent than terreic acid, and the structural consequences of covalent modification by these two inhibitors are fundamentally different. The MurA-fosfomycin complex exists in the closed enzyme conformation, with the Cys115-fosfomycin adduct buried in the active site. In contrast, the dead-end complex with terreic acid is open, is free of UNAG, and has the Cys115-terreic acid adduct solvent-exposed. It appears that terreic acid reacts with Cys115 in the closed, binary state of the enzyme, but that the resulting Cys115-terreic acid adduct imposes steric clashes in the active site. As a consequence, the loop containing Cys115 rearranges, the enzyme opens, and UNAG is released. The differential kinetic and structural characteristics of MurA inactivation by terreic acid and fosfomycin reflect the importance of noncovalent binding potential, even for covalent inhibitors, in ensuring inactivation efficiency and specificity.
Han
Huijong
H
Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Yang
Yan
Y
Olesen
Sanne H
SH
Becker
Andreas
A
Betzi
Stephane
S
Schönbrunn
Ernst
E
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism; D001665:Binding Sites; D020134:Catalytic Domain; D002473:Cell Wall / Q000201:enzymology* / Q000378:metabolism; D018360:Crystallography, X-Ray; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism; D004926:Escherichia coli / Q000201:enzymology / Q000378:metabolism; D007700:Kinetics; D008958:Models, Molecular; D017434:Protein Structure, Tertiary; D011809:Quinones / Q000737:chemistry / Q000378:metabolism
D004791:Enzyme Inhibitors; D011809:Quinones; D019883:Alkyl and Aryl Transferases; C022566:UDP-N-acetylglucosamine 1-carboxyvinyltransferase; C009400:terreic acid
Biochemistry. 1994 Sep 6;33(35):10646-51
8075065
J Bacteriol. 1985 Jun;162(3):1061-7
2987181
Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9
16945528
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
9757107
FEBS Lett. 1992 Apr 27;301(3):271-6
1577165
Eur J Biochem. 1993 Dec 15;218(3):861-70
8281938
Structure. 1996 Sep 15;4(9):1065-75
8805592
J Bacteriol. 1982 Jul;151(1):477-9
6282810
J Biol Chem. 2005 Feb 4;280(5):3757-63
15531591
J Biol Chem. 2005 Apr 8;280(14):14070-5
15701635
J Med Chem. 2008 Aug 28;51(16):5143-7
18672863
Structure. 1996 Dec 15;4(12):1465-74
8994972
Jpn J Antibiot. 1980 Mar;33(3):320-8
7190624
Ann N Y Acad Sci. 1974 May 10;235(0):364-86
4605290
Proteins. 2000 Aug 1;40(2):290-8
10842342
Biochemistry. 2000 Mar 7;39(9):2164-73
10694381
Biochemistry. 1996 Apr 16;35(15):4923-8
8664284
Phytochemistry. 2010 Feb;71(2-3):312-24
19939419
Proteins. 2008 May 1;71(2):1032-7
18247346
Microbiology (Reading). 1999 Nov;145 ( Pt 11):3177-3184
10589726
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
2025413
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2227-32
10051623
Anal Biochem. 1979 Nov 15;100(1):95-7
161695